Literature DB >> 2197092

Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

M López-Brea1, T Alarcón.   

Abstract

Escherichia coli and Klebsiella pneumoniae resistant to fluoroquinolones were isolated from an infected Hickman catheter in a 43-year-old diabetic patient who had previously been treated with a 24-day course of ciprofloxacin (200 mg/12 h i.v.). MICs and MBCs of nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, pefloxacin and fleroxacin were determined for the strains using the methodology recommended by the NCCLS. Both strains were resistant to all the quinolones tested. Since long-term treatment with quinolones might favour the emergence of quinolone resistance or colonization with quinolone-resistant organisms, it is important to monitor for the development of bacterial resistance during therapy with the new fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197092     DOI: 10.1007/bf01973741

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

Review 1.  Mechanisms of resistance to quinolones and clinical perspectives.

Authors:  L J Piddock; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Ciprofloxacin therapy in cystic fibrosis.

Authors:  J A Raeburn; J R Govan; W M McCrae; A P Greening; P S Collier; M E Hodson; M C Goodchild
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

4.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.

Authors:  C C Sanders; C Watanakunakorn
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

Review 5.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

6.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

7.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo.

Authors:  P B Fernandes; C W Hanson; J M Stamm; C Vojtko; N L Shipkowitz; E St Martin
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

8.  In-vitro selection of bacteria resistant to the 4-quinolone agents.

Authors:  D I Limb; D J Dabbs; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

9.  Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

Authors:  M J Haverkorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

10.  Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.

Authors:  J W Ogle; L B Reller; M L Vasil
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

View more
  10 in total

1.  First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

Authors:  M Jonsson; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

Authors:  A L Barry; P C Fuchs; M A Pfaller; S D Allen; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

3.  Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients.

Authors:  M G van Kraaij; A W Dekker; E Peters; A Fluit; L F Verdonck; M Rozenberg-Arska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

4.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

6.  Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.

Authors:  J A García-Rodríguez; M J Fresnadillo; M I García; E García-Sánchez; J E García-Sánchez; I Trujillano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

7.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

Authors:  P Heisig; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 9.  Mechanisms of quinolone resistance.

Authors:  B Wiedemann; P Heisig
Journal:  Infection       Date:  1994       Impact factor: 3.553

10.  Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients.

Authors:  W V Kern; A Markus; E Andriof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.